Center For Mental Health Ruse EOOD
- Address
- Bulevard Tutrakan 20, 7003 Rousse, Bulgaria
Center For Mental Health Ruse EOOD - Psychiatric Disorders Research
The Center For Mental Health Ruse EOOD is a specialized psychiatric research facility dedicated to advancing the treatment of major mental health disorders through innovative clinical trials. The center has established particular expertise in evaluating novel therapeutic agents and adjunctive treatment strategies for mood disorders, anxiety disorders, and psychotic conditions, with a strong emphasis on addressing treatment-resistant populations and improving patient outcomes through precision medicine approaches.
- Major Depressive Disorder including treatment-resistant depression, anhedonia subtypes, and relapse prevention studies
- Generalized Anxiety Disorder investigating both monotherapy and adjunctive treatment approaches
- Bipolar I Disorder focusing on acute manic episodes and mixed features
- Schizophrenia evaluating adjunctive therapies for patients with inadequate response to antipsychotics
The center's research portfolio demonstrates comprehensive experience with phase II and phase III clinical trials, utilizing standardized assessment tools such as the HAM-A, MADRS, YMRS, and other validated rating scales. Their expertise extends to complex study designs including dose-response evaluations, long-term safety monitoring, and investigations of novel pharmacological mechanisms including kappa opioid receptor antagonists and other innovative compounds targeting both acute symptom management and sustained remission in psychiatric populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Intra-Cellular Therapies Inc.2active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Intra-Cellular Therapies Inc.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Center For Mental Health Ruse EOOD
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjunctive Aticaprant and Antidepressant Therapy for Relapse Prevention in Major Depressive Disorder with Moderate-to-Severe Anhedonia: A Randomized, Double-Blind Study | Janssen Cilag International | Phase III | Not Recruiting | Dec 2024 | Feb 2025 |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 9-(4-CYCLOHEXYLOXYPHENYL)-7-METHYL-3,4-DIHYDROPYRAZINO[2,1-C][1,2,4]THIADIAZINE 2,2-DIOXIDE | 2 | Unknown | 2025-10-07 | 2025-10-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.